Menu
Fechar
HRS4R
Vull donar

ARIADNA ROQUÉ LLOVERAS

Oncologia de Precisió de Girona
Firma
ARIADNA ROQUÉ-LLOVERAS
Posició
Investigador/a Pre-doctoral – R1
Investigadors/es Pre-doctorals – R1
Projectes
Publicacions

Projectes

Oncologia de Precisió de Girona

Y-RNAs AS NON-INVASIVE BIOMARKERS FOR EARLY CANCER DETECTION

Codi oficial: IDEAS246813BRUN Data inici: 01/12/2024 Data fi: 30/11/2026 Investigador/a principal: JOAN BRUNET VIDAL, GEMMA VIÑAS VILARÓ Organisme finançador: ASSOCIACIÓ ESPANYOLA CONTRA EL CÀNCER
Oncologia de Precisió de Girona

PRISMA-II: Estratificación del riesgo de cáncer de mama/ovario mediante incorporación del polygenic risk score. Validación en portadoras, cohorte prospectiva, y viabilidad de la secuenciación de genoma

Codi oficial: PI23/01047- PRISMA Data inici: 01/01/2024 Data fi: 31/12/2026 Investigador/a principal: ARIADNA ROQUÉ LLOVERAS, JOAN BRUNET VIDAL Organisme finançador: INSTITUTO DE SALUD CARLOS III

Publicacions

López-Fernández A, Duran-Lozano L, Villacampa G, Pardo M, Pérez E, Darder E, Vallmajó A, Alfonso R, Cruellas M, Roqué A, Cartró M, Bareas A, Carrasco E, Rezqallah A, Jimenez-Macedo AR, Torres-Esquius S, Torres M, Lopez C, Espinosa M, Teulé A, Munté E, Tuset N, Diez O, Feliubadaló L, Lázaro C, Llort G, Carver T, Ficorella L, Mavaddat N, Mercadé A, Antoniou AC, Brunet J, Ramon Y Cajal T, Balmaña J

A randomized study of 2 risk assessment models for individualized breast cancer risk estimation.

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2025, 117, 1593-1604 dx.doi.org/10.1093/jnci/djaf067
Sanvisens A, Vidal-Vila A, Puigdemont M, Viñas G, Roqué-Lloveras A, Del Barco S, Pérez-Bueno F, Trallero J, Marcos-Gragera R, Renart G

Population-based analysis of breast cancer incidence and mortality: overall and age-specific temporal trends over 40-year period in Girona, Spain.

BREAST CANCER RESEARCH AND TREATMENT, 2025, 212, 97-105 dx.doi.org/10.1007/s10549-025-07704-8
Roqué-Lloveras, A, Pérez-Bueno, F, Pozo-Ariza, X, Polonio-Alcalá, E, Ausellé-Bosch, S, Oliveras, G, Viñas, G, Puig, T

Breast Cancer Stem Cells and Immunogenicity Profile in High-Risk Early Triple-Negative Breast Cancer: A Pilot Study

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 dx.doi.org/10.3390/ijms26093960
Sabaté-Ortega, J, Ribera-Montserrat, A, del Barco, S, Roqué-Lloveras, A, Fort-Culillas, R, Carmona-García, MC, Liñan, R, Polonio-Alcalá, E, Carbó-Vilavedra, G, Ramos-Oliver, I, Bujons-Buscarons, E, Montañés-Ferrer, C, Viñas, G, Pla-Juher, H

Double trouble, managing bilateral inflammatory breast cancer: a case report

Frontiers in oncology, 2025, 15 dx.doi.org/10.3389/fonc.2025.1595513
Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA

Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin

Pharmaceuticals, 2022, 15 dx.doi.org/10.3390/ph15010019
OnCovid Study Group, Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Bower M, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Ottaviani D, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Queirolo P, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué Lloveras A, Newsom-Davis T, Sharkey R, Roldán E, Reyes R, Zoratto F, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Berardi R, Giusti R, Mazzoni F, Guida A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, Van Hemelrijck M, Diamantis N, Gennari A, Cortellini A

Time-Dependent COVID-19 Mortality in Patients With Cancer An Updated Analysis of the OnCovid Registry

JAMA Oncology, 2022, 8, 114-122 dx.doi.org/10.1001/jamaoncol.2021.6199
Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom-Davis T, Handford J, Sita-Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona-García MC, Sharkey R, García-Illescas D, Rizzo G, Perachino M, Saoudi-Gonzalez N, Doonga K, Fox L, Roldán E, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Martinez-Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A, OnCovid study group

Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

LANCET ONCOLOGY, 2022, 23, 865-875 dx.doi.org/10.1016/S1470-2045(22)00273-X
Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felip E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, Patriarca A, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A, OnCovid study group

Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

LANCET ONCOLOGY, 2021, 22, 1669-1680 dx.doi.org/10.1016/S1470-2045(21)00573-8
Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Seguí E, Biello F, Generali D, Grisanti S, Seeva P, Rizzo G, Libertini M, Maconi A, Moss C, Russell B, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Chopra N, Tondini CA, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué A, Lee AJX, Newsom-Davis T, García-Illescas D, Reyes R, Wong YNS, Ferrante D, Scotti L, Marco-Hernández J, Ruiz-Camps I, Patriarca A, Rimassa L, Chiudinelli L, Franchi M, Santoro A, Prat A, Gennari A, Van Hemelrijck M, Tabernero J, Diamantis N, Pinato DJ, OnCovid study group

Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

Journal for ImmunoTherapy of Cancer, 2021, 9 dx.doi.org/10.1136/jitc-2020-002277

Formulari de contacte

Coneix l’IDIBGI!

 menu